Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

BBNX - Beta Bionics, Inc. Последние новости | Finranks

Home

/

BBNX

B

Beta Bionics, Inc. (BBNX)

NGM – Цена в реальном времени. Валюта: USD

9.82

-0.03 (-0.30%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Beta Bionics, Inc. (BBNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Beta Bionics, Inc. (BBNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Beta Bionics, Inc. (BBNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review

First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review

Leading contributors in the First Eagle Small Cap Opportunity Fund this quarter included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor. Oil States International shares rallied on very strong bookings during the quarter and improved operator-powered solutions and services inside the wellbore. The leading detractors in the quarter were Vital Farms, Alphatec Holdings, Beta Bionics, SI-BONE. and Herc Holdings.

Beta Bionics to Present at the Bank of America Securities Health Care Conference

Beta Bionics to Present at the Bank of America Securities Health Care Conference

IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time).

Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript

Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript

Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript

Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates

Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates

Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.52 per share a year ago.

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026.

Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?

Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?

Beta Bionics, Inc. (BBNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Видео

No Data

There is no data to display

Пресс-релизы

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026.

Beta Bionics, Inc. Investigated by the Portnoy Law Firm

Beta Bionics, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Beta Bionics, Inc. (“Beta Bionics" or the "Company") (NASDAQ: BBNX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 28, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).

BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).